Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03372720
Other study ID # OSU-17261
Secondary ID NCI-2017-02051
Status Completed
Phase N/A
First received
Last updated
Start date May 11, 2018
Est. completion date April 12, 2022

Study information

Verified date April 2022
Source Ohio State University Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized pilot trial studies how well fractional carbon dioxide (CO2) laser therapy works in minimizing genitourinary syndrome of menopause (GSM) in gynecological cancer survivors. Fractional CO2 laser therapy may reduce symptoms of GSM in survivors of gynecologic cancers.


Description:

PRIMARY OBJECTIVES: I. To conduct a pilot trial to estimate the proportion of gynecologic cancer patients with vaginal dryness or dyspareunia, who will have an improvement in their symptoms with vaginal laser therapy compared to sham treatment based on the Vaginal Assessment Scale (VAS). SECONDARY OBJECTIVES: I. To evaluate toxicity associated with vaginal laser therapy in this population. II. To determine how many women with the defined patient eligibility will complete all treatments. III. To determine the feasibility of the crossover design for potential use in a phase III trial. IV. To determine improvement in objective findings of vaginal atrophy with vaginal laser therapy versus sham treatment. V. To determine improvement in sexual function as measured by Female Sexual Function Index (FSFI), Female Sexual Distress Scale-Revised (FSDS), and scales for sexual satisfaction and behavior with vaginal laser therapy versus sham treatment. VI. To determine improvement in urinary symptoms of urogenital atrophy with vaginal laser therapy versus sham treatment using the Urogenital Distress Inventory (UDI). VII. To demonstrate satisfaction with vaginal fractional CO2 laser therapy. OUTLINE: Patients are randomized in to 1 of 2 arms. ARM I: Patients undergo fractional CO2 laser therapy at 3 time points 30 days apart. ARM II: Patients undergo sham laser therapy at 3 time points 30 days apart. Patients may then crossover to Arm I. After completion of study, patients are followed up at 1 month.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date April 12, 2022
Est. primary completion date December 18, 2019
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: - Women with cervical, endometrial, vaginal, vulvar or ovarian cancer who have completed all cancer related treatment >= 6 months prior to enrollment - Any form of hysterectomy, including radical hysterectomy permitted - Must have no evidence of recurrent disease on pelvic exam within past 3 months - Radiation therapy is permitted but not required - Patient reported dyspareunia and/or vaginal dryness with severity of >= 4 on a scale from 0 (none) to 10 (most severe) that has been persistent over >= 4 weeks and/or the inability to be sexually active due to pain Exclusion Criteria: - Patients with recurrent or metastatic endometrial, vaginal, vulvar, cervical, or ovarian cancer - Pelvic organ prolapse stage II or higher - Prior reconstructive pelvic surgery involving mesh - Hormone replacement therapy or vaginal estrogen therapy within 6 weeks prior to enrollment

Study Design


Intervention

Procedure:
Laser Therapy
Undergo fractional CO2 laser therapy
Other:
Questionnaire Administration
Ancillary studies
Procedure:
Sham Intervention
Undergo sham laser therapy

Locations

Country Name City State
United States Johns Hopkins University Baltimore Maryland
United States Ohio State University Comprehensive Cancer Center Columbus Ohio
United States Sanford Roger Maris Cancer Center Fargo North Dakota
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Ohio State University Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in genitourinary syndrome of menopause (GSM) symptoms Will be assessed by the Vaginal Assessment Scale (VAS). Will be summarized and compared between the treatment arms using a two-sample t-test or a Wilcoxon rank sum test, with a two-sided alternative for each. Will also analyze this endpoint graphically by plotting the VAS scores through time by treatment arm. Additionally, will correlate the scores from the VAS with other validated measures using a Spearman's correlation coefficient in an exploratory manner. Baseline to 12 weeks
Secondary Feasibility as measured by number of patients able to complete 3 study visitis A crossover design to determine the feasibility of the crossover design for potential use in a phase III trial by summarizing the proportion of patients who are unable to tolerate the study treatment prior to completing the 3 treatments Up to 1 month
Secondary Improvement in objective findings of vaginal atrophy Will determine improvement in objective findings of vaginal atrophy with vaginal laser therapy versus sham treatment. Up to 1 month
Secondary Improvement in sexual function by FSFI Will determine improvement in sexual function as measured by Female Sexual Function Index (FSFI) Up to 1 year
Secondary Improvement in sexual function FSDS Will determine improvement in sexual function as measured by Female Sexual Distress Scale-Revised (FSDS) Up to 1 year
Secondary Improvement in urinary symptoms Will determine improvement in urinary symptoms of urogenital atrophy with vaginal laser therapy versus sham treatment using the Urogenital Distress Inventory (UDI). The change in dyspareunia and dryness between baseline (T0) and T4 will be calculated and compared between the treatment and sham arms using a two sample t-test or Wilcoxon rank sum test. Up to 1 month
Secondary Incidence of adverse events Adverse event grading will be done according to the NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE) Up to 1 month
Secondary Number of patients complete all treatments Summarize the proportion of patients who are able to tolerate the study treatment and complete the 3 treatments. Up to 1 month
Secondary Satisfaction with vaginal fractional CO2 laser therapy Patients will be asked to rate their satisfaction with the procedure on a likert-type scale of 1-10 with 1 being completely dissatisfied and 10 being extremely satisfied. Participants will be asked to rate their satisfaction on this scale after each treatment and at follow-up. Up to 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT05494580 - Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer Phase 1/Phase 2
Withdrawn NCT02530606 - Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer N/A
Active, not recruiting NCT02244502 - Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) Phase 1/Phase 2
Terminated NCT02218502 - Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses N/A
Terminated NCT01936974 - (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma Phase 2
Recruiting NCT02073500 - Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Completed NCT00756847 - Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors Phase 1
Withdrawn NCT02878980 - An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients N/A
Active, not recruiting NCT02194387 - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members N/A
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) Phase 1/Phase 2
Recruiting NCT04251052 - A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer N/A
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Completed NCT00989651 - Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Phase 1
Not yet recruiting NCT05591560 - Itraconazole in Advanced Ovarian Cancer N/A
Completed NCT01481701 - A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma Phase 2
Completed NCT00181701 - Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin Phase 2
Terminated NCT00047632 - Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer Phase 3
Recruiting NCT03302884 - Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma N/A
Completed NCT02166905 - DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Phase 1/Phase 2
Recruiting NCT04851119 - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Phase 1/Phase 2

External Links